Blog
Talacotuzumab Biosimilar: Advancing CD123-Targeted Cancer Therapy
Talacotuzumab, a humanized monoclonal antibody targeting CD123, has shown promise in treating acute myeloid leukemia (AML) and other hematologic malignancies. As a key immunotherapy, it
…
27th Nov 2024